Abstract

ObjectiveTo ascertain contemporary approaches to the collection, reporting and analysis of adverse events (AEs) in randomised controlled trials (RCTs) with a primary efficacy outcome.DesignA review of clinical trials of drug interventions from four high impact medical journals.Data sourcesElectronic contents table of the BMJ, the Journal of the American Medical Association (JAMA), the Lancet and the New England Journal of Medicine (NEJM) were searched for reports of original RCTs published between September 2015 and September 2016.MethodsA prepiloted checklist was used and single data extraction was performed by three reviewers with independent check of a randomly sampled subset to verify quality. We extracted data on collection methods, assessment of severity and causality, reporting criteria, analysis methods and presentation of AE data.ResultsWe identified 184 eligible reports (BMJ n=3; JAMA n=38, Lancet n=62 and NEJM n=81). Sixty-two per cent reported some form of spontaneous AE collection but only 29% included details of specific prompts used to ascertain AE data. Numbers that withdrew from the trial were well reported (80%), however only 35% of these reported whether withdrawals were due to AEs. Results presented and analysis performed was predominantly on ‘patients with at least one event’ with 84% of studies ignoring repeated events. Despite a lack of power to undertake formal hypothesis testing, 47% performed such tests for binary outcomes.ConclusionsThis review highlighted that the collection, reporting and analysis of AE data in clinical trials is inconsistent and RCTs as a source of safety data are underused. Areas to improve include reducing information loss when analysing at patient level and inappropriate practice of underpowered multiple hypothesis testing. Implementation of standard reporting practices could enable a more accurate synthesis of safety data and development of guidance for statistical methodology to assess causality of AEs could facilitate better statistical practice.

Highlights

  • The methods to analyse and report outcomes to measure benefit from randomised controlled trials (RCTs) are well developed but this progress has not been matched for adverse event (AE) outcomes

  • ►► This is the first review to examine and quantify the methods used for adverse event analysis in randomised controlled trials published in high impact general medical journals

  • We found that the collection, reporting and analysis of AE data in clinical trials is inconsistent and RCTs as a source of safety data are underused

Read more

Summary

Introduction

The methods to analyse and report outcomes to measure benefit from randomised controlled trials (RCTs) are well developed but this progress has not been matched for adverse event (AE) outcomes. ►► This is the first review to examine and quantify the methods used for adverse event analysis in randomised controlled trials published in high impact general medical journals. ►► Articles included in this review were published in four of the top ranked general medical journals, results are likely to be biased towards better practice. RCTs provide an opportunity to compare rates of AEs between arms allowing causality to be evaluated. There are many challenges associated with analysing and reporting AEs in clinical trials. Often large numbers of AEs are reported during a study, sometimes exceeding the number of patients in the clinical trial. Performing hypothesis tests on these AEs would lead to issues of multiplicity; any adjustment for multiplicity would make a ‘finding untenable’.3 4 The use of hypothesis testing may result in the medicinal product being deemed unsafe and a trial being halted too early due to a chance imbalance, or deemed safe and Phillips R, et al BMJ Open 2019;9:e024537. doi:10.1136/bmjopen-2018-024537

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call